Bio-Techne/Asuragen AmplideX Nanopore Carrier Plus Kit
Bio-Techne subsidiary Asuragen said this week that it has teamed up with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit for carrier screening research. The research-use-only kit combines AmplideX long-range PCR and nanopore sequencing long reads to directly capture large genomic variants. The 11-gene panel includes the most prevalent recommended genes — CFTR, CYP21A2, F8 inversions, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2, and TNXB — that can't be detected accurately with short-read sequencing methods. The kit also includes software to allow for straightforward analysis without requiring advanced bioinformatics resources, Asuragen said.
Cofactor Genomics OncoPrism for Colorectal, Breast, Bladder, and Kidney Cancer
Cofactor Genomics has launched OncoPrism genomic classifiers for colorectal, breast, bladder, and kidney cancer. The new products build on the company's OncoPrism classifier, which received a positive coverage decision in October from Medicare administrative contractor Palmetto GBA. The four new cancer profiles also follow the clinical validation and launch of OncoPrism-NSCLC for non-small cell lung cancer. In general, OncoPrism tests evaluate a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's response to immune checkpoint inhibitor (ICI) immunotherapy, classifying patients into low, medium, and high groups. In addition, OncoPrism can be used for patient stratification and subtyping in studies and clinical trials, the company said.
Wren Laboratories NETest 2.0
Wren Laboratories, a Branford, Connecticut-based liquid biopsy diagnostics provider, has launched NETest 2.0 for neuroendocrine tumor (NET) diagnostics. NETest 2.0 uses an artificial intelligence-enhanced, noninvasive 51-gene mRNA expression algorithm to help diagnose NETs from 1 mL of blood collected in a proprietary tube. According to the company, the assay has greater than 95 percent sensitivity for detecting NETs, greater than 90 percent accuracy in identifying progressive disease, and predicts patient response to peptide receptor radionuclide therapy with a 98 percent positive predictive value and a 93 percent negative predictive value. The company offers the test under CLIA, CAP, and New York State Department of Heath CLEP certification. With the new launch, the company has discontinued the first generation of the assay.
For more recently launched products and services, please visit the New Products page on our website.